Previously, we have reported that SGLT2 is expressed in pancreatic, prostate, and brain tumors [4, 5], and furthermore reported that SGLT2 inhibitors reduced the uptake of a specific SGLT glucose tracer, α-methyl-4-[18F]fluoro-4-deoxy-α-D-glucopyranoside (Me4FDG), into tumors grown in nude mice and reduced growth [4]. This evidence concerns the gene SLC5A2 and brain neoplasm.